(Q33203294)

23 July 2017

title

Biologic agents for the treatment of juvenile rheumatoid arthritis: current status (English)

1 reference

juvenile rheumatoid arthritis

23 July 2017

main subject

1 reference

0 references

3

Daniel Lovell

1 reference

23 July 2017

Ruy Carrasco

1

1 reference

23 July 2017

Judith A Smith

series ordinal

2

1 reference

23 July 2017

publication date

1 January 2004

1 reference

23 July 2017

1 reference

23 July 2017

volume

6

1 reference

23 July 2017

issue

3

1 reference

23 July 2017

page(s)

137-146

1 reference

https://scigraph.springernature.com/pub.10.2165/00148581-200406030-00001

23 July 2017

exact match

0 references

cites work

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

1 reference

12 December 2020

Infliximab treatment for rheumatic disease: clinical and radiological efficacy

1 reference

12 December 2020

Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis

1 reference

12 December 2020

Etanercept in systemic juvenile idiopathic arthritis

1 reference

12 December 2020

Preliminary definition of improvement in juvenile arthritis

1 reference

12 December 2020

TNF alpha and the TNF receptor superfamily: structure-function relationship(s).

1 reference

12 December 2020

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

1 reference

12 December 2020

The role of tumor necrosis factor in health and disease.

1 reference

12 December 2020

Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type

1 reference

12 December 2020

Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis

1 reference

12 December 2020

New indications for treatment of chronic inflammation by TNF-alpha blockade

1 reference

12 December 2020

Etanercept in the treatment of macrophage activation syndrome.

1 reference

12 December 2020

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein

1 reference

12 December 2020

Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group

1 reference

12 December 2020

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

12 December 2020

Current treatment of juvenile rheumatoid arthritis.

1 reference

12 December 2020

Onset of multiple sclerosis associated with anti-TNF therapy.

1 reference

12 December 2020

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

12 December 2020

The pathophysiology of tumor necrosis factors

1 reference

12 December 2020

Tumour necrosis factor α stimulates resorption and inhibits synthesis of proteoglycan in cartilage

1 reference

12 December 2020

Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody

1 reference

12 December 2020

Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage.

1 reference

12 December 2020

Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management

1 reference

12 December 2020

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

12 December 2020

Methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis

1 reference

12 December 2020

Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled

1 reference

12 December 2020

A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: a pilot study

1 reference

12 December 2020

Etanercept in four children with therapy-resistant systemic juvenile idiopathic arthritis.

1 reference

12 December 2020

Safety and efficacy of high dose etanercept in treatment of juvenile rheumatoid arthritis.

1 reference

12 December 2020

Serum cytokines in juvenile rheumatoid arthritis. Correlation with conventional inflammation parameters and clinical subtypes

1 reference

12 December 2020

Immunological evaluation of cytokine and anticytokine immunotherapy in vivo: what have we learnt?

1 reference

12 December 2020

Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial

1 reference

12 December 2020

Cytokine levels in serum of patients with juvenile rheumatoid arthritis.

1 reference

12 December 2020

Etanercept therapy in children with treatment-resistant uveitis

1 reference

12 December 2020

Abnormal regulation of interleukin 6 in systemic juvenile idiopathic arthritis.

1 reference

12 December 2020

Uncoupling of inflammatory and destructive mechanisms in arthritis

1 reference

12 December 2020

The long-term effect of methotrexate therapy on the liver in patients with juvenile rheumatoid arthritis

1 reference

12 December 2020

Life-threatening reversible bone marrow toxicity in a rheumatoid arthritis patient switched from leflunomide to infliximab

1 reference

12 December 2020

Etanercept in the treatment of adult patients with Still's disease

1 reference

12 December 2020

Recommendations about the prevention and management of tuberculosis in patients taking infliximab

1 reference

12 December 2020

Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha

1 reference

12 December 2020

The relationship of hepatotoxic risk factors and liver histology in methotrexate therapy for juvenile rheumatoid arthritis.

1 reference

12 December 2020

Anti-interleukin 6 receptor antibody treatment in rheumatic disease

1 reference

12 December 2020

Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy

1 reference

12 December 2020

Differences in the profiles of circulating levels of soluble tumor necrosis factor receptors and interleukin 1 receptor antagonist reflect the heterogeneity of the subgroups of juvenile rheumatoid arthritis

1 reference

12 December 2020

Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study

1 reference

12 December 2020

Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum

1 reference

12 December 2020

Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration

1 reference

12 December 2020

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis

1 reference

12 December 2020

Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial

1 reference

12 December 2020

10.2165/00148581-200406030-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

23 July 2017

1041232714

0 references

1 reference